Pirenoxine
| Code | Size | Price |
|---|
| TAR-T21229-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Pirenoxine is an agent with anti-cataractogenesis activity by interacting with calcium ions or selenite which could lead to the formation of lens cataract.
CAS:
1043-21-6
Formula:
C16H8N2O5
Molecular Weight:
308.249
Purity:
0.98
SMILES:
OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1
References
1. Tsuneyoshi Y, Higuchi A, Negishi K, Tsubota K. Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy. Sci Rep. 2017 Jul 28;7(1):6819. doi: 10.1038/s41598-017-07208-6. PubMed PMID: 28754903; PubMed Central PMCID: PMC5533700.
2. Ueno A, Yamaoka S, Ito Y, Kotake T, Nakazawa Y, Nagai N. Improvement of Dissolution Rate and Stability in a Pirenoxine Ophthalmic Suspension by the Bead Mill Methods. Yakugaku Zasshi. 2017;137(5):635-641. doi: 10.1248/yakushi.16-00267. Japanese. PubMed PMID: 28458295.
3. Liao Z, Yu X, Yao Q, Yi P. Interaction between pirenoxine and bovine serum albumin in aqueous solution. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Aug 14;129:314-9. doi: 10.1016/j.saa.2014.03.057. Epub 2014 Apr 1. PubMed PMID: 24747854.
4. Hu CC, Liao JH, Hsu KY, Lin IL, Tsai MH, Wu WH, Wei TT, Huang YS, Chiu SJ, Chen HY, Wu SH, Wu TH. Role of pirenoxine in the effects of catalin on in vitro ultraviolet-induced lens protein turbidity and selenite-induced cataractogenesis in vivo. Mol Vis. 2011;17:1862-70. Epub 2011 Jul 12. PubMed PMID: 21850160; PubMed Central PMCID: PMC3144730.